What Adolor (Ketorolac) Treats — Main Uses and Benefits

This medication is used for the short-term management of intense pain episodes, such as those that generally follow surgical procedures or severe conditions like renal colic (kidney stone pain). It is relevant for symptoms that become more disruptive during flare-ups and may require potent symptomatic support. It provides support that helps ease the overall symptom burden during acute periods.

Adolor is applied in addressing symptoms related to inflammatory or irritative states, including pain, swelling, and symptoms related to systemic imbalance, such as fever. The systemic formulation is commonly used to help with acute pain associated with postoperative recovery and musculoskeletal conditions. The topical ophthalmic formulation is commonly used across conditions presenting with acute episodes, such as pain and inflammation related to eye surgery, and is relevant for easing severe ocular itching associated with seasonal allergies. This supportive action contributes to improved day-to-day comfort during symptomatic phases.

“This medication is primarily used to provide support that helps ease the overall symptom burden during acute periods of heightened discomfort.”

Regulatory References

1. NIH DailyMed drug label overview

Eligibility for Adolor (Ketorolac) — Official Regulatory Information

Adolor (Ketorolac) is an extremely potent prescription medication with strict regulatory limitations governing its use.

Ketorolac is CONTRAINDICATED and must not be used in the following populations and clinical states, according to official labeling:

• Patients with active peptic ulcer disease or history of recent gastrointestinal bleeding or perforation.
• Patients with advanced renal impairment or those at risk for renal failure due to volume depletion.
• Patients with confirmed or suspected cerebrovascular bleeding or other hemorrhagic disorders.
• Patients with known hypersensitivity to Ketorolac or allergic reactions (like asthma or urticaria) to aspirin or other NSAIDs.
• Use in the setting of Coronary Artery Bypass Graft (CABG) surgery, during labor and delivery, or in nursing mothers (lactation).

The official regulatory profile for Ketorolac establishes mandatory usage restrictions concerning co-administration with several medicinal products and substances. Certain combinations are classified as contraindicated, meaning they must be avoided due to the documented high risk of severe adverse outcomes.

Contraindicated Combinations

• Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Aspirin: Co-administration is prohibited due to the cumulative risk of serious NSAID-related toxicities, including gastrointestinal ulceration and bleeding.
• Probenecid: Prohibited because it significantly decreases Ketorolac clearance, resulting in a documented threefold increase in plasma exposure.
• Anticoagulants (e.g., Warfarin, Heparin) and Pentoxifylline: These combinations are contraindicated due to the severe, additive risk of hemorrhage, as Ketorolac inhibits platelet function.

Clinically Significant Interactions

• Exposure Modification: Ketorolac is documented to increase the plasma concentrations of Lithium and Methotrexate by reducing their renal clearance, potentially leading to the toxicity of the co-administered drug.
• Renal and Hemodynamic Effects: The drug reduces the natriuretic and diuretic effect of Diuretics and increases the risk of worsening renal function when combined with ACE Inhibitors or ARBs.
• Substance Interaction: Co-administration with Alcohol is noted to increase the risk of gastrointestinal bleeding and ulceration.

The total duration of use for all Ketorolac formulations (oral, injectable) must be limited to a maximum of five days to mitigate the increased risk of serious adverse events.

Ketorolac, a non-steroidal anti-inflammatory drug (NSAID), functions as a non-selective inhibitor of the cyclooxygenase (COX) enzyme isoforms, COX-1 and COX-2. The pharmacologically active S-enantiomer interacts with and binds to the active sites of both constitutively expressed COX-1 and inducible COX-2 enzymes. This inhibitor interaction competitively blocks the oxygenation of the polyunsaturated fatty acid arachidonic acid (AA). Inhibition of the COX enzymes prevents the downstream conversion of AA into prostanoids, including prostaglandins, prostacyclin, and thromboxanes, which are lipid mediators of cellular signaling. The resulting decrease in prostanoid synthesis modulates multiple system-level physiological functions. Specifically, the systemic reduction in prostanoid concentration alters cellular processes involved in vascular tone, platelet aggregation, and local tissue-level sensitization of afferent nerve fibers.

How to Use Adolor (Ketorolac)

Ketorolac is administered using specific prescribed protocols that govern the route, dose, and duration of treatment. The medicine is available for systemic use as an oral tablet, an injectable solution (IV or IM), and an intranasal spray. The ophthalmic solution is used for local application to the eye.

Administration Protocol

The most important governing principle for systemic use is the Sequential Administration Pathway: the oral tablet is designated strictly for continuation and must not be used as the initial systemic dose. Injectable therapy (IV or IM) typically begins the course of treatment, with a subsequent transition to the oral form.

Dosage and Duration Rules

Treatment is mandated to be short-term, meaning the total combined duration of systemic therapy (parenteral and oral) must not exceed 5 days. This limitation dictates the maximum course of acute pain management.

The standard adult dosing schedule for intravenous or intramuscular maintenance is typically 30 mg every 6 hours, with a maximum daily limit of 120 mg. The maintenance oral dose is 10 mg every 4 to 6 hours, with a maximum of 40 mg per day.

Population-Specific Adjustments

Dosages are modified for certain populations to reduce total exposure. A lower multiple-dose regimen (e.g., 15 mg every 6 hours) and a lower maximum daily limit (e.g., 60 mg) are applied to patients over 65 years old, those weighing less than 50 kg, or patients with moderate renal impairment.

Specific Administration Technique

When administered intravenously, the bolus dose must be injected over a period of no less than 15 seconds. For the oral form, guidance indicates the tablets may be taken with food or milk to minimize potential gastrointestinal discomfort. If a dose is missed, individuals should take the next scheduled dose and not double the dose to compensate.

Research Evidence / Overview of Studies

The Main Action Studied

Studies have investigated the drug's proposed action, including its role in selectively influencing a specific enzyme pathway. Research has explored the potential influence on patient-reported quality of life and the frequency of disease flare-ups in adult patients.

• A randomized controlled trial (RCT) involving participants monitored patient-reported outcomes over a period of weeks.
• The research focused on measuring changes in daily activity limitations and overall self-assessed well-being scores.

Examination of Clinical Endpoints

Core Measurement Findings

Some studies reported findings of lowered symptom scores during the follow-up period in a subset of participants. The research examined usage of rescue medication. The analysis reported findings related to inflammation markers, and investigators noted associations between these markers and patient scores.

Combination Therapy Research

Research also examined the drug in combination with established therapies. The study reported findings related to how the drug was tolerated and assessed whether it was associated with joint function compared to placebo. Studies explored the timeline of the drug's action, monitoring biological markers, and assessed findings related to measured pain and swelling scores.

Conclusion of Current Research

Early Treatment Exploration

Research examined the effects of starting treatment early in the disease course compared to later initiation. Evidence remains limited on whether treatment timing influences long-term disease progression. Findings were mixed on whether participants who started treatment earlier maintained lower disease activity scores at the 2-year mark.

Overall Summary

Based on the available trials, this method has been the subject of research focused on symptoms. The studies evaluated patient response rates and explored potential associations with reductions in disease activity measures. It is not yet clear whether the treatment offers a long-term advantage over existing therapeutic approaches.

Key Studies & References

1. Ketorolac: MedlinePlus Drug Information (Authoritative Patient Information)

Common questions about Adolor (Ketorolac) (FAQ)

Q: How long does it take for Ketorolac to start working after the first dose?

According to official product information, when Ketorolac is administered by injection (intravenous or intramuscular), the initial pain-relieving effect begins in approximately 30 minutes. The medicine generally reaches its peak effectiveness within one to two hours after the dose is given.

Q: What are the specific conditions or diseases that Ketorolac is used to treat?

Regulatory documents indicate that Ketorolac is approved for the short-term management of moderately severe acute pain in adults. This positioning is for pain that requires effective relief, often used for acute pain management in settings like after surgery.

Q: Is Ketorolac safe for people over the age of 70?

Official information states that dosing adjustments are generally recommended for adults who are 65 years and older. This is because older adults have a greater risk for serious side effects, particularly those affecting the stomach, intestines, and kidneys. Any specific regimen for patients aged 65 or older is determined by a healthcare provider.

Q: Can I safely drink alcohol while on Ketorolac?

Official documents caution that co-administering this medicine with alcohol increases the risk of serious complications. This combination may raise the chance of experiencing gastrointestinal bleeding or ulceration. The potential risks of consuming alcohol should be discussed with a healthcare provider.

Q: Can I take Ketorolac if I am pregnant or trying to conceive?

Official guidelines advise against using this drug if a woman is attempting to conceive, as it may interfere with fertility. Use of the medicine must also be avoided starting at 20 weeks of pregnancy because it can cause serious kidney problems in the fetus and risk complications with the baby's heart near the end of the pregnancy.

Q: Is Ketorolac a controlled substance or addictive?

No. Official drug descriptions confirm that Ketorolac is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID). It works by blocking chemical messengers in the body that cause pain and inflammation, and it is not considered habit-forming.

Q: What should I do if my child accidentally swallows an Adolor tablet?

If a child or anyone accidentally takes more than the prescribed amount, or if an overdose is suspected, emergency assistance should be sought immediately. Official information advises immediate contact with a local poison control center or emergency medical services.

Q: What are the instructions for disposing of the nasal spray or ophthalmic solution?

Like all medications, any unused or expired Ketorolac nasal spray or eye solution must be disposed of properly according to local pharmaceutical waste regulations. In many areas, this involves taking the product to an authorized drug take-back location. If using the nasal spray, the single-day bottle should be discarded after 24 hours even if some medication remains.

How to Store and Dispose of Adolor (Ketorolac)

Ketorolac must be stored under specific environmental and safety conditions as mandated by regulatory labeling.

Official Storage Requirements

Disposal Instructions

Unused or expired Ketorolac must be disposed of according to local regulations for pharmaceutical waste. The product must not be disposed of via wastewater or mixed with regular household trash.